CORRECTION

Open Access

Correction to: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer



Zhuo-yuan Lin^{1,2†}, Guo Chen^{1†}, Yan-qiong Zhang^{3,7,8†}, Hui-chan He^{1†}, Yu-xiang Liang¹, Jian-heng Ye^{1,7,8}, Ying-ke Liang^{1,4}, Ru-jun Mo^{1,4}, Jian-ming Lu^{1,4}, Yang-jia Zhuo^{1,4}, Yu Zheng^{2,4}, Fu-neng Jiang¹, Zhao-dong Han¹, Shu-lin Wu^{7,8}, Wei-de Zhong^{1,4,5,6*} and Chin-Lee Wu^{1,7,8*}

Correction to: Mol Cancer (2017) 16:48 https://doi.org/10.1186/s12943-017-0615-x

After publication of the article [1], the author reported that this article contained some errors.

The photograph of sh-NC in Fig. 1c was misplaced. The correct version of the figure and the figure legend is presented below.

Author details

¹Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China. ²Department of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510260, China. ³Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China. ⁴Guangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. ⁵Urology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510230, China. ⁶Graduate school of Jinan University, Guangzhou 510632, China. ⁷Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. ⁸Department of Urology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

Published online: 06 August 2019

Reference

 Lin Z-y, Chen G, Zhang Y-q, He H-c, Liang Y-x, Ye J-h, Liang Y-k, Mo R-j, Jianming L, Zhuo Y-j, Zheng Y, Jiang F-n, Han Z-d, Shu-lin W, Zhong W-d, Chin-Lee W. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer. Mol Cancer. 2017;16:48. https://doi.org/10.1186/s12943-017-0615-x.


* Correspondence: zhongwd2009@live.cn; cwu2@mgh.harvard.edu [†]Zhuo-yuan Lin, Guo Chen, Yan-qiong Zhang and Hui-chan He contributed equally to this work.

¹Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China

Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.



induced tumor xenografts. **a** Kaplan-Meier analyses of biochemical recurrence (BCR)-free survival and overall survival of PCa patients based on miR- 30d expression in Taylor and TCGA datasets. **b** LNCaP cells stably expressing miR-30d formed significantly larger tumor nodules and remarkably speeded up tumor xenografts growth compared with the controls. Conversely, PCa cells that permanently suppressed miR-30d expression led to the smaller tumor nodules and the slower tumor growth compared with the control. **c** Immunohistochemical analysis using pan-endothelial marker CD31 antibody. **d** VEGFA protein expression in different groups detected by Western blot analysis. Data were presented as Mean \pm SD. **P* < 0.05. ***P* < 0.01